Claudio Benadiva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claudio Benadiva has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
John Nulsen
Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
2 shared publicationsLawrence Engmann
Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
2 shared publications- Alan B. Copperman
Mount Sinai Medical Center, New York, NY, USA
1 shared publication - Basil Tarlatzis
First Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Perifereiaki Odos Thessalonikis-N. Efkarpias 564 29, Thessaloniki, Greece
1 shared publication Daniel Griffin
Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
1 shared publicationDonald Maier
The Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut, USA
1 shared publication
Latest Publications
- 1 August 2014
- Published by Elsevier in Fertility and Sterility
- Vol. 102 (2) , 405-409
Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates
- 1 August 2014
- Published by Elsevier in Fertility and Sterility
- Vol. 102 (2) , 405-409
Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates
- Open Access
- 1 January 2013
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 11 (1) , 20
Optimal usage of the GnRH antagonists: a review of the literature
Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection. This review focuses on the recent literature on the use of GnRH antagonists and provides guidelines for optimal use in light of increasing evidence showing that GnRH antagonists are safe and effective, allowing flexibility of treatment in a wide range of patient populations. This includes patients undergoing first-line controlled ovarian stimulation, poor responders, and women diagnosed with polycystic ovary syndrome. The GnRH antagonist offers a viable alternative to the long agonists, providing a shorter duration of treatment with fewer injections and with no adverse effects on assisted reproductive technology outcome. This results in a significantly lower amount of gonadotropins required, which is likely to lead to improved patient compliance.
- 1 January 2013
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 11 (1) , 20
Open AccessOptimal usage of the GnRH antagonists: a review of the literature
Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection. This review focuses on the recent literature on the use of GnRH antagonists and provides guidelines for optimal use in light of increasing evidence showing that GnRH antagonists are safe and effective, allowing flexibility of treatment in a wide range of patient populations. This includes patients undergoing first-line controlled ovarian stimulation, poor responders, and women diagnosed with polycystic ovary syndrome. The GnRH antagonist offers a viable alternative to the long agonists, providing a shorter duration of treatment with fewer injections and with no adverse effects on assisted reproductive technology outcome. This results in a significantly lower amount of gonadotropins required, which is likely to lead to improved patient compliance.
- 30 September 2012
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 25 (3) , 329-330
Intensive luteal phase support after GnRH agonist trigger: it does help
- 30 September 2012
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 25 (3) , 329-330
Intensive luteal phase support after GnRH agonist trigger: it does help
- Open Access
- 1 January 2011
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 9 (1) , 147
New algorithm for OHSS prevention
Ovarian hyperstimulation syndrome (OHSS) still remains a life-threatening complication of in vitro fertilization treatment (IVF), keeping patients and especially those, who previously experienced OHSS, from attempting infertility treatment and childbearing. The recent implementation of four new modalities: the GnRH antagonist protocol, GnRH agonist (GnRHa) triggering of ovulation, blastocyst transfer and embryo/oocyte vitrification, renders feasible the elimination of OHSS in connection with ovarian hyperstimulation for IVF treatment. The proposed current algorithm is based on the number of follicles developed after ovarian stimulation, setting a cut-off level at the development of 18 or more follicles. Further, fulfilling this criterion, the algorithm is based on four decision-making points: the final day of patient work-up, the day of triggering final oocyte maturation, day-1 post oocyte pick-up (OPU) and day-5 post OPU.
- 1 January 2011
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 9 (1) , 147
Open AccessNew algorithm for OHSS prevention
Ovarian hyperstimulation syndrome (OHSS) still remains a life-threatening complication of in vitro fertilization treatment (IVF), keeping patients and especially those, who previously experienced OHSS, from attempting infertility treatment and childbearing. The recent implementation of four new modalities: the GnRH antagonist protocol, GnRH agonist (GnRHa) triggering of ovulation, blastocyst transfer and embryo/oocyte vitrification, renders feasible the elimination of OHSS in connection with ovarian hyperstimulation for IVF treatment. The proposed current algorithm is based on the number of follicles developed after ovarian stimulation, setting a cut-off level at the development of 18 or more follicles. Further, fulfilling this criterion, the algorithm is based on four decision-making points: the final day of patient work-up, the day of triggering final oocyte maturation, day-1 post oocyte pick-up (OPU) and day-5 post OPU.
- 1 December 1999
- Published by Elsevier in Fertility and Sterility
- Vol. 72 (6) , 1041-1044
Intracytoplasmic sperm injection overcomes previous fertilization failure with conventional in vitro fertilization
- 1 December 1999
- Published by Elsevier in Fertility and Sterility
- Vol. 72 (6) , 1041-1044
Intracytoplasmic sperm injection overcomes previous fertilization failure with conventional in vitro fertilization